R J Barst, L J Rubin, W A Long, M D McGoon, S Rich, D B Badesch, B M Groves, V F Tapson, R C Bourge, B H Brundage, S K Koerner, D Langleben, C A Keller, S Murali, B F Uretsky, L M Clayton, M M Jöbsis, S D Blackburn, D Shortino, J W Crow
BACKGROUND: Primary pulmonary hypertension is a progressive disease for which no treatment has been shown in a prospective, randomized trial to improve survival. METHODS: We conducted a 12-week prospective, randomized, multicenter open trial comparing the effects of the continuous intravenous infusion of epoprostenol (formerly called prostacyclin) plus conventional therapy with those of conventional therapy alone in 81 patients with severe primary pulmonary hypertension (New York Heart Association functional class III or IV)...
February 1, 1996: New England Journal of Medicine